Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

MLA

Van Lint, Maria Teresa, et al. “Treatment of Acute Graft-versus-Host Disease with Prednisolone: Significant Survival Advantage for Day +5 Responders and No Advantage for Nonresponders Receiving Anti-Thymocyte Globulin.” Blood, vol. 107, no. 10, May 2006, pp. 4177–81. EBSCOhost, https://doi.org/10.1182/blood-2005-12-4851.

APA

Van Lint, M. T., Milone, G., Leotta, S., Uderzo, C., Scimè, R., Dallorso, S., Locasciulli, A., Guidi, S., Mordini, N., Sica, S., Cudillo, L., Fagioli, F., Selleri, C., Bruno, B., Arcese, W., & Bacigalupo, A. (2006). Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 107(10), 4177–4181. https://doi.org/10.1182/blood-2005-12-4851

Chicago

Van Lint, Maria Teresa, Giuseppe Milone, Salvatore Leotta, Cornelio Uderzo, Rosanna Scimè, Sandro Dallorso, Anna Locasciulli, et al. 2006. “Treatment of Acute Graft-versus-Host Disease with Prednisolone: Significant Survival Advantage for Day +5 Responders and No Advantage for Nonresponders Receiving Anti-Thymocyte Globulin.” Blood 107 (10): 4177–81. doi:10.1182/blood-2005-12-4851.